A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

Status:
Terminated

Trial end date:
2009-08-01

Target enrollment:

Participant gender:

This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases

Phase 1/Phase 2

Novartis Pharmaceuticals